BG101500A - The use of [r-(z)]-alpha -(methoxyimino)-alpha -(1-azabicyclo [2,2,2]-oct-3-yl) acetonitrile for reducing the formation of amyloidene beta a4 in alzheimer's disease - Google Patents

The use of [r-(z)]-alpha -(methoxyimino)-alpha -(1-azabicyclo [2,2,2]-oct-3-yl) acetonitrile for reducing the formation of amyloidene beta a4 in alzheimer's disease

Info

Publication number
BG101500A
BG101500A BG101500A BG10150097A BG101500A BG 101500 A BG101500 A BG 101500A BG 101500 A BG101500 A BG 101500A BG 10150097 A BG10150097 A BG 10150097A BG 101500 A BG101500 A BG 101500A
Authority
BG
Bulgaria
Prior art keywords
alpha
disease
alzheimer
acetonitrile
amyloidene
Prior art date
Application number
BG101500A
Other languages
Bulgarian (bg)
English (en)
Inventor
Roger Markwell
Julie Hawkins
Carol Gray
Original Assignee
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham P.L.C. filed Critical Smithkline Beecham P.L.C.
Publication of BG101500A publication Critical patent/BG101500A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BG101500A 1994-10-25 1997-05-20 The use of [r-(z)]-alpha -(methoxyimino)-alpha -(1-azabicyclo [2,2,2]-oct-3-yl) acetonitrile for reducing the formation of amyloidene beta a4 in alzheimer's disease BG101500A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9421472A GB9421472D0 (en) 1994-10-25 1994-10-25 Novel methods
PCT/EP1995/004082 WO1996012486A1 (en) 1994-10-25 1995-10-17 Use of [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo [2.2.2] oct-3-yl) acetonitrile to reduce amyloid beta a4 formation in alzheimer's disease

Publications (1)

Publication Number Publication Date
BG101500A true BG101500A (en) 1998-01-30

Family

ID=10763350

Family Applications (1)

Application Number Title Priority Date Filing Date
BG101500A BG101500A (en) 1994-10-25 1997-05-20 The use of [r-(z)]-alpha -(methoxyimino)-alpha -(1-azabicyclo [2,2,2]-oct-3-yl) acetonitrile for reducing the formation of amyloidene beta a4 in alzheimer's disease

Country Status (21)

Country Link
US (1) US5891887A (de)
EP (1) EP0786998B1 (de)
JP (1) JPH10509697A (de)
KR (1) KR100393365B1 (de)
CN (1) CN1085529C (de)
AT (1) ATE214926T1 (de)
AU (1) AU698695B2 (de)
BG (1) BG101500A (de)
BR (1) BR9509433A (de)
CZ (1) CZ287370B6 (de)
DE (1) DE69526102T2 (de)
DK (1) DK0786998T3 (de)
ES (1) ES2173977T3 (de)
GB (1) GB9421472D0 (de)
HU (1) HUT77007A (de)
NO (1) NO312055B1 (de)
NZ (1) NZ295155A (de)
PT (1) PT786998E (de)
SK (1) SK50497A3 (de)
WO (1) WO1996012486A1 (de)
ZA (1) ZA958946B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU751607B2 (en) * 1995-07-29 2002-08-22 Smithkline Beecham Plc Method of treatment of dementia
GB9619074D0 (en) * 1996-09-12 1996-10-23 Smithkline Beecham Plc Composition
DE19641180A1 (de) * 1996-09-24 1998-03-26 Schering Ag Verfahren zur Darstellung von APP-Sekretase Modulation und deren Verwendung als Mittel zur Behandlung der Alzheimer'schen Erkrankung
JP2002506031A (ja) 1998-03-11 2002-02-26 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 組成物
GB9815383D0 (en) * 1998-07-15 1998-09-16 Smithkline Beecham Plc Novel method of treatment
US6245884B1 (en) * 1998-10-16 2001-06-12 Vivian Y. H. Hook Secretases related to alzheimer's dementia
US7816149B2 (en) * 2004-03-29 2010-10-19 Applied Photonics Worldwide, Inc. Nanobioprocessor for protein and cell therapy
GB0428170D0 (en) * 2004-12-23 2005-01-26 Biopartners Ltd Mono and Combination Therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG48315A1 (en) * 1989-04-13 1998-04-17 Beecham Group Plc Novel compounds
US5385915A (en) * 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
US5242932A (en) * 1991-12-17 1993-09-07 The Rockefeller University Treatment of amyloidosis associated with alzheimer disease
JPH0725786A (ja) * 1990-05-16 1995-01-27 Univ Rockefeller アルツハイマー病を伴うアミロイドーシスの治療
MX9300875A (es) * 1992-02-20 1993-08-31 Smithkline Beecham Plc Procedimiento para la preparacion de compuestos azabiciclicos.
WO1994009370A1 (en) * 1992-10-09 1994-04-28 Massachusetts Institute Of Technology Release of alzheimer amyloid precursor stimulated by activation of muscarinic acetylcholine receptors
GB9409705D0 (en) * 1994-05-14 1994-07-06 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
HK1002057A1 (en) 1998-07-31
HUT77007A (hu) 1998-03-02
DK0786998T3 (da) 2002-07-15
NO971899L (no) 1997-04-24
CZ125197A3 (en) 1997-07-16
MX9703077A (es) 1997-07-31
PT786998E (pt) 2002-09-30
NO312055B1 (no) 2002-03-11
ES2173977T3 (es) 2002-11-01
CZ287370B6 (en) 2000-11-15
US5891887A (en) 1999-04-06
JPH10509697A (ja) 1998-09-22
DE69526102D1 (de) 2002-05-02
BR9509433A (pt) 1997-09-16
AU698695B2 (en) 1998-11-05
KR100393365B1 (ko) 2003-12-18
GB9421472D0 (en) 1994-12-07
NZ295155A (en) 2000-07-28
AU3843195A (en) 1996-05-15
EP0786998B1 (de) 2002-03-27
DE69526102T2 (de) 2002-10-31
EP0786998A1 (de) 1997-08-06
ZA958946B (en) 1996-08-20
ATE214926T1 (de) 2002-04-15
CN1085529C (zh) 2002-05-29
WO1996012486A1 (en) 1996-05-02
CN1170365A (zh) 1998-01-14
NO971899D0 (no) 1997-04-24
SK50497A3 (en) 1997-09-10
KR970706816A (ko) 1997-12-01

Similar Documents

Publication Publication Date Title
BE2018C038I2 (de)
GR3030867T3 (en) Guanidine derivatives useful in therapy
AU4515985A (en) New tetrapyrrole therapeutic agents
HRP920667A2 (en) Application of fultripine active substance for preventing muscle deformation
HUT51136A (en) Process for producing pharmaceutical compositions for treating schisophreny, containing l-deprenil as active component
UA39936C2 (uk) 2-(2,6-дифторфеніл)-4-(2-етокси-4-трет-бутилфеніл)-2-оксазолін, спосіб мiтицидної обробки та мiтицидна композиція
UA29464C2 (uk) Активне начало лікарського засобу, призначеного для лікування хвороби паркінсона і синдромів паркінсона та спосіб одержання вказаного лікарського засобу
HUT73433A (en) Process for preparing pharmaceutical compositions containing riluzole for treating aids-related neural disorders
GB2285219A (en) Use of norastemizole for the treatment of allergic disorders
GR3036774T3 (en) Compositions containing G-CSF and TNF binding protein.
BG101500A (en) The use of [r-(z)]-alpha -(methoxyimino)-alpha -(1-azabicyclo [2,2,2]-oct-3-yl) acetonitrile for reducing the formation of amyloidene beta a4 in alzheimer's disease
GR3032041T3 (en) Idebenone compositions for treating Alzheimer's disease.
LTIP1534A (en) Medicinal preparations for prophylaxis and treating metabolic disturbance of lipoids and cholesterin
AU655958B2 (en) Use of quisqualate-receptor antagonists for treating Parkinson's disease
ZA876740B (en) Derivatives of 4,5-dihydrooxazoles,a process for their preparation and their use
ATE157010T1 (de) Amylin oder amylinanaloga enthaltende zusammensetzung, welche auch wahlweise insulin enthält, zur behandlung von anorexie und verwandten zuständen
AU1807592A (en) New combination preparation for treatment of parkinson's disease
EP0353910A3 (en) Human interferon-gamma, process for preparing said human interferon-gamma, and its use
HUT60145A (en) Process for producing pharmaceutical composition comprising human interleukin-2 and suitable for treating pneumothorax
IL103499A0 (en) Pharmaceutical compositions for treating anxiety in benzodiazepine withdrawn patients
UA28288A (uk) Спосіб лікування шизофренії
MX9703359A (es) Acidos 2,2-dicloroalcancarboxilicos, proceso para su preparacion, medicamentos que los contienen y su uso para tratar resistencia a la insulina.
GB9017746D0 (en) Composition for treatment of respiratory ailments